GlassScriptPhysician profile
William Shelton
NPI 1952349268
$2,248.92
in general payments reported to CMS, 2019-2025
33 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $186 · 2021: $573 · 2022: $634 · 2023: $245 · 2024: $227 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.23 | 2021-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $380.61 | 2019-2025 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $263.83 | 2020-2024 | Yupelri |
| Amgen INC. | $155.87 | 2020-2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $127.18 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.76 | 2021-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.99 | 2019-2022 | |
| Viatris Specialty LLC | $61.23 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $57.62 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $55.23 | 2022 | |
| Astellas Pharma US INC | $54.95 | 2019-2021 | |
| Lilly USA, LLC | $50.32 | 2022-2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $45.77 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.90 | 2021-2024 | |
| Insulet Corporation | $39.74 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34.64 | 2020-2022 | |
| Amarin Pharma, INC. | $34.19 | 2021 | |
| Ironshore Pharmaceuticals INC. | $32.97 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $30.05 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.32 | 2020-2021 | |
| Medtronic, INC. | $25.95 | 2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $25.07 | 2022 | |
| Glaxosmithkline, LLC. | $18.45 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.13 | 2025 | |
| Sanofi Pasteur INC. | $14.57 | 2023 | |
| Dexcom, INC. | $14.05 | 2024 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $13.49 | 2025 | |
| Seqirus USA INC | $12.89 | 2022 | |
| Therapeuticsmd, INC. | $12.50 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.48 | 2019 | |
| Pfizer INC. | $12.46 | 2019 | |
| Eisai INC. | $11.74 | 2020 | |
| Tactile Systems Technology INC | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.